The role of bevacizumab on tumour angiogenesis and in the management of gynaecological cancers: A review

被引：43
作者：
Chellappan, Dinesh Kumar [1 ]
Leng, Kun Hooi [2 ]
Jia, Lee Jia [2 ]
Aziz, Nur Amirah Binti Abdul [2 ]
Hoong, Wong Chun [2 ]
Qian, Yap Cheng [2 ]
Ling, Fam Yi [2 ]
Wei, Gwee Sing [2 ]
Ying, Tiong [2 ]
Chellian, Jestin [1 ]
Gupta, Gaurav [3 ]
Dua, Kamal [4 ]
机构：
[1] Int Med Univ, Sch Pharm, Dept Life Sci, Kuala Lumpur 57000, Malaysia
[2] Int Med Univ, Sch Pharm, Kuala Lumpur 57000, Malaysia
[3] Jaipur Natl Univ, Sch Pharmaceut Sci, Jaipur 302017, Rajasthan, India
[4] Univ Technol Sydney, Grad Sch Hlth, Discipline Pharm, Sydney, NSW 2007, Australia
来源：
BIOMEDICINE & PHARMACOTHERAPY | 2018年 / 102卷
关键词：
Bevacizumab; Cervical cancer; Endometrial cancer; Ovarian cancer; ENDOTHELIAL-GROWTH-FACTOR; PHASE-II TRIAL; RECURRENT OVARIAN-CANCER; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; EPITHELIAL OVARIAN; ENDOMETRIAL CANCER; COLORECTAL-CANCER; VASCULAR-PERMEABILITY; HUMAN-PAPILLOMAVIRUS; FACTOR VEGF;
D O I：
10.1016/j.biopha.2018.03.061
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Objective: The study aims to analyze the effectiveness of bevacizumab in addressing the complications associated with gynecological cancers and evaluates effective treatments for various gynecological cancers. Methods: The study follows a systematic review approach that has been implemented to analyze the qualitative published data from previous studies. Studies related with the trials of angiogenesis and bevacizumab were selected in the review. Results: In general, the management of gynecological cancers include chemotherapy, surgery and radiation therapy. Results suggest bevacizumab as an effective treatment modality for cervical and several other cancers. Overall, bevacizumab showed promising results in improving the overall survival rate of gynecological cancer patients through the combination of bevacizumab with other chemotherapeutic agents. Conclusion: Bevacizumab possess less documented adverse effects when compared to other chemotherapeutic agents. The manifestation and severity of adverse effects reported varied according to the chemotherapeutic agent(s) that were used with bevacizumab in combination therapy. Overall, bevacizumab effectively improved the survival rate in patients with several gynaecological cancers.
引用
收藏
页码：1127 / 1144
页数：18
相关论文
共 224 条
  • [1] RECURRENT ADENOCARCINOMA OF THE ENDOMETRIUM - A CLINICAL AND HISTOPATHOLOGICAL STUDY OF 379 PATIENTS
    AALDERS, JG
    ABELER, V
    KOLSTAD, P
    [J]. GYNECOLOGIC ONCOLOGY, 1984, 17 (01) : 85 - 103
  • [2] Abcouwer S. F., 2013, J CLIN CELL IMMUN S1, V1, DOI [10.4172/2155-9899, DOI 10.4172/2155-9899]
  • [3] ABULAFIA O, 1995, OBSTET GYNECOL, V86, P479, DOI 10.1016/0029-7844(95)00203-4
  • [4] Adusumilli P, 2017, INDIAN J MED PAEDIAT, V38, P22, DOI 10.4103/0971-5851.203511
  • [5] OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
    Aghajanian, Carol
    Blank, Stephanie V.
    Goff, Barbara A.
    Judson, Patricia L.
    Teneriello, Michael G.
    Husain, Amreen
    Sovak, Mika A.
    Yi, Jing
    Nycum, Lawrence R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) : 2039 - 2045
  • [6] Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study
    Aghajanian, Carol
    Sill, Michael W.
    Darcy, Kathleen M.
    Greer, Benjamin
    McMeekin, D. Scott
    Rose, Peter G.
    Rotmensch, Jacob
    Barnes, Mack N.
    Hanjani, Parviz
    Leslie, Kimberly K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (16) : 2259 - 2265
  • [7] Phase II trial of combination bevacizumab and temsirolimus in the treatment of A recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group study
    Alvarez, Edwin A.
    Brady, William E.
    Walker, Joan L.
    Rotmensch, Jacob
    Zhou, Xun C.
    Kendrick, James E.
    Yamada, S. Diane
    Schilder, Jeanne M.
    Cohn, David E.
    Harrison, Charles R.
    Moore, Kathleen N.
    Aghajanian, Carol
    [J]. GYNECOLOGIC ONCOLOGY, 2013, 129 (01) : 22 - 27
  • [8] [Anonymous], INDIAN J PALLIAT C S
  • [9] [Anonymous], CURR OPIN ONCOL
  • [10] [Anonymous], SARCOMA
12345678910